|
Abstract
|
“The grand orchestrator,” “Universal Amplifier,” “double-edged sword,” and “Undruggable” are just some of the
Myc oncogene so-called names. It has been around 40 years since the discovery of the Myc, and it remains in the
mainstream of cancer treatment drugs. Myc is part of basic helix–loop–helix leucine zipper (bHLH-LZ) superfamily
proteins, and its dysregulation can be seen in many malignant human tumors. It dysregulates critical
pathways in cells that are connected to each other, such as proliferation, growth, cell cycle, and cell adhesion,
impacts miRNAs action, intercellular metabolism, DNA replication, differentiation, microenvironment regulation,
angiogenesis, and metastasis. Myc, surprisingly, is used in stem cell research too. Its family includes three
members, MYC, MYCN, and MYCL, and each dysfunction was observed in different cancer types. This review
aims to introduce Myc and its function in the body. Besides, Myc deregulatory mechanisms in cancer cells, their
intricate aspects will be discussed. We will look at promising drugs and Myc-based therapies. Finally, Myc and its
role in stemness, Myc pathways based on PPI network analysis, and future insights will be explained
|